{
  "docId": "019de511-a3d8-7540-920c-8c3b0e395e63",
  "docSlug": "e4e57b1dfc1f9bbb0961f2a7846fe008",
  "documentTitle": "Avantor | Results Presentation Deck | 18 slides",
  "authorId": "avantor",
  "authorName": "Avantor",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 18,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide uses a table-like layout to present KPIs alongside qualitative drivers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de511-a3d8-7540-920c-8c3b0e395e63/5",
  "deckHref": "/decks/019de511-a3d8-7540-920c-8c3b0e395e63",
  "deckJsonHref": "/decks/019de511-a3d8-7540-920c-8c3b0e395e63.json",
  "deckAnchorHref": "/decks/019de511-a3d8-7540-920c-8c3b0e395e63#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.5,
        "x": 0.45,
        "y": 0.15
      },
      "kind": "list",
      "text": "Strong growth in all regions led by Biopharma; ~8.5% Core / ~1.7% COVID-19 tailwinds. Volume, inflation management & proprietary growth; ~180bps margin expansion. Continued track record of execution; Lower interest and tax expense. Strong EBITDA performance partially offset by growth investments; Higher cash tax timing and CARES ACT expiry. Down 0.3X from Q2; Committed to 2-4X target leverage.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6492bf3b-7bf4-4f9c-9235-542a9dd6837c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.22,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1: Excludes equity issuance proceeds of ~$970M",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e33315b2-b288-4d3a-815f-0fcb62021561",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.96,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "table",
      "text": "Organic revenue 10.2% | Adjusted EBITDA growth 25.8% | Fully diluted adjusted EPS growth 47.6% | Free cash flow $229.3M | Adjusted net leverage 3.5X",
      "attrs": null,
      "subkind": "kpi",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a7c50ec-6448-4fc3-a32a-93aa1737e451",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Q3 performance",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1b93210-4e22-4f8b-b52f-a9a193659df5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 5,
      "beatId": "5d0b649d-d11e-4ba9-9cad-a1f996d0ab16",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "Q3 performance and financial metrics",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}